Carcinoma, Non-Small-Cell Lung
Conditions
Keywords
Metastatic Non-Small Cell Lung Cancer, NSCLC, Chinese patients, dabrafenib, trametinib, BRAF V600E, treatment naive, pre-treated
Brief summary
This was a single-arm, open label, multicenter phase II, study of dabrafenib in combination with trametinib in Chinese participants with BRAF V600E mutation positive, stage IV NSCLC (American joint committee on cancer staging 8th edition). Approximately 40 Chinese adults were to be enrolled in this study. Participants were to be treated with dabrafenib in combination with trametinib until disease progression, start of a new anti-neoplastic therapy, unacceptable toxicity, pregnancy, withdrawal of consent, lost to follow-up, physician's decision, death, or if study be terminated by the sponsor. The general study design was discussed and agreed with China National Medical Products Administration and was based on a similar design used in the global pivotal phase II study (Study 113928 / NCT01336634).
Interventions
DRUGDabrafenib
Dabrafenib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Dabrafenib will be administered orally twice daily (150 mg BID) for Days 1-21 of a 21-day cycle.
DRUGTrametinib
Trametinib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Trametinib will be administered orally once daily (2 mg QD) for Days 1-21 of a 21-day cycle
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed diagnosis of Stage IV NSCLC (according to AJCC 8th edition) that is BRAF V600E mutation-positive by local test result from a qualified assay (NMPA and/or MOH-approved) * Previously treated or untreated for metastatic NSCLC: 1. Participants previously treated should have received no more than 3 prior systemic therapies for metastatic disease, with at least one prior platinum based chemotherapy, and should have documented disease progression on a prior treatment regimen (i.e. RECIST 1.1) 2. Participants who have received prior therapy with checkpoint inhibitor therapy (i.e. anti-PD-1/PD-L1) must have had objective evidence of disease progression (i.e. RECIST v1.1) while on or after this therapy prior to enrollment. 3. Participants with EGFR or ALK mutation who have previously received therapy with EGFR or ALK inhibitor(s) respectively are eligible * Measurable disease per RECIST v1.1 * Anticipated life expectancy of at least 3 months * ECOG performance status ≤ 2. * Adequate bone marrow and organ function as defined by the following laboratory values without continuous supportive treatment (such as blood transfusion, coagulation factors and/or platelet infusion, or red/white blood cell growth factor administration) as assessed by local laboratory for eligibility: Hemoglobin ≥ 9 g/dL; Absolute neutrophil count ≥ 1.5 × 109/L; Platelets ≥ 100 × 109/L; PT/INR and PTT ≤ 1.5 x ULN; Serum creatinine \< 1.5 mg/dL; Total bilirubin ≤ 1.5 × ULN (upper limit of normal) except for participants with Gilbert's syndrome who may only be included if the total bilirubin is ≤ 3.0 × ULN or direct bilirubin ≤ 1.5 × ULN; AST and ALT ≤ 2.5 × ULN, except for participant with liver metastasis, who may only be included if AST/ALT ≤ 5.0 × ULN Albumin ≥ 2.5 g/dL * Left ventricular ejection fraction (LVEF) ≥ lower limit of institutional normal (LLN) as assessed by ECHO or MUGA scan
Exclusion criteria
* Participants with brain or leptomeningeal metastases are excluded if their these metastases are: symptomatic or treated but not clinically and radiographically stable 3 weeks after local therapy or asymptomatic and untreated but \>1 cm in the longest dimension * Previous treatment with a BRAF inhibitor or a MEK inhibitor * All prior anti-cancer treatment-related toxicities must be Grade 2 or less according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE version 4.03; NCI, 2009) at the time of enrollment * Prior anti-cancer treatment within the last 2 weeks, and prior treatment with immune checkpoint inhibitors within 4 weeks preceding the first dose of the study treatment. * Current use of a prohibited medication * Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study treatments, their excipients, and/or dimethyl sulfoxide (DMSO). * Participants with known history for testing positive for Human Immunodeficiency Virus (HIV) * History of another malignancy \<3 years prior to starting study treatment or any malignancy with confirmed activating RAS-mutation. * Cardiac or cardiac repolarization abnormality * A history or current evidence/risk of retinal vein occlusion (RVO) or serous retinopathy * History or current interstitial lung disease or non-infectious pneumonitis * Any serious or unstable pre-existing medical conditions (aside from malignancy exceptions specified above), psychiatric disorders, or other conditions that, in the opinion of the investigator, could interfere with the participant's safety, obtaining informed consent, or compliance with study procedures * Pregnant or nursing (lactating) women. * Sexually active males (including those that have had a vasectomy) must use a condom during intercourse and should not father a child during this period. The amount of time a patient must use a condom for 16 weeks post treatment discontinuation * Participants with active Hepatitis B infection (HbsAg positive) * Participants with positive test for hepatitis C ribonucleic acid (HCV RNA) * Concurrent participation in other clinical trials using experimental therapies
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (ORR), Central Independent Review Assessed by RECIST v1.1 | From baseline until disease progression, death, lost to follow-up or withdrawal of consent, whichever occurs first, assessed up to approximately 50 months from treatment initiation | Overall Response Rate (ORR) was defined as the proportion of participants with best overall response (BOR) of complete response (CR) or partial response (PR), as per central independent review assessment and according to RECIST 1.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS), Investigator Assessed by RECIST v1.1 | From baseline until disease progression or death due to any cause, whichever occurs first, assessed up to approximately 50 months from treatment initiation | Progression Free Survival (PFS) was defined as the time from the date of first dose to the date of the first documented progression or death due to any cause. PFS was assessed via local review according to RECIST 1.1. PFS was censored if no PFS event was observed before the first to occur between: (i) the analysis cut-off date, and (ii) the date when a new anti-neoplastic therapy is started. The censoring date was the date of the last adequate tumor assessment prior to cut-off/start of new anti-neoplastic therapy. |
| Duration of Response (DoR), Investigator Assessed by RECIST v1.1 | From first documented response until first documented progression or death due to any cause, whichever occurs first, assessed up to approximately 50 months from treatment initiation | Duration of Response (DoR) only applies to participants whose Best Overall Response (BOR) was complete response (CR) or partial response (PR) according to RECIST 1.1 based on tumor response data per local review. The start date is the date of first documented response of CR or PR (i.e. the start date of response, not the date when response was confirmed), and the end date is defined as the date of the first documented progression or death due to any cause. Participants continuing without progression or death were censored at the date of their last adequate tumor assessment. |
| Overall Survival (OS) | From baseline until death due to any cause, assessed up to approximately 50 months from treatment initiation | Overall Survival (OS) was defined as the time from date of first dose to date of death due to any cause. If a participant was not known to have died, then OS was censored at the latest date the participant was known to be alive (on or before the cut-off date). |
| Trough Concentration of Dabrafenib | Pre-dose sample at visits week 3, 6 and 12 | Plasma concentration of dabrafenib were calculated by visit/sampling time point and summarized using descriptive statistics. |
| Trough Concentration of Dabrafenib Metabolites (Hydroxy-dabrafenib, and Desmethyl-dabrafenib) | Pre-dose sample at visits week 3, 6 and 12 | Plasma concentration of dabrafenib metabolites (hydroxy-dabrafenib, and desmethyl-dabrafenib) were calculated by visit/sampling time point and summarized using descriptive statistics. |
| Overall Response Rate (ORR), Investigator Assessed by RECIST v1.1 | From baseline until disease progression, death, lost to follow-up or withdrawal of consent, whichever occurs first, assessed up to approximately 50 months from treatment initiation | Overall Response Rate (ORR) was defined as the proportion of participants with best overall response (BOR) of complete response (CR) or partial response (PR) by Investigator assessment as per RECIST 1.1 criteria. |
| Mean Change From Baseline in the European Quality of Life (EuroQol)- 5 Dimensions, 5 Level Questionnaire (EQ-5D-5L) | Baseline (BL), Week 12, End of Treatment (up to approximately 50 months after treatment initiation) | The EQ-5D-5L is a standardized tool for measuring health-related quality of life (HRQoL). The instrument includes a descriptive system and a visual analogue scale. The descriptive system covers five dimensions (Mobility, Self-care, Usual activities, Pain/discomfort, Anxiety/depression), each with five severity levels ranging from 0 (no problems) to 5 (extreme problems) resulting in a 5-digit health code. In China, a country-specific value set is used to convert the five-digit health state into a utility score, ranging from \<0 (worse than death) to 1.0 (perfect health). A positive change from baseline indicates improvement; a negative change indicates deterioration. The Visual Analog Scale (VAS) is a 0-100 self-rated health scale, where 0 is the worst and 100 the best imaginable health. A positive change reflects perceived improvement. |
| Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) Scale | Baseline (BL), Week 12, End of Treatment (up to approximately 50 months after treatment initiation) | The EORTC QLQ-C30 is a 30-item questionnaire that patients complete, consisting of both multi-item scales and single-item measures. It includes five functional scales, three symptom scales, six single items, and a Global Health Status/Quality of Life (GHS/QoL) scale. The GHS/QoL scale has seven possible response scores ranging from 1 (very poor) to 7 (excellent), which are averaged and transformed to a 0-100 scale. A higher score on this scale indicates a better quality of life. The change from baseline in GHS/QoL scores is calculated. A positive change from baseline indicated improvement in the patient's quality of life. |
| Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Baseline (BL), Week 12, End of Treatment (up to approximately 50 months after treatment initiation) | The EORTC QLQ-LC13 is a lung cancer-specific module designed to supplement the EORTC QLQ-C30 core questionnaire. It focuses on symptoms and side effects particularly relevant to lung cancer patients, including: Cough, Dyspnea (Shortness of breath), Hemoptysis (Coughing up blood), Sore Mouth/Tongue, Dysphagia (Trouble swallowing), Peripheral neuropathy (Tingling Hands/Feet), Alopecia (Hair Loss) and Pain in chest, arm, shoulder, or other areas and an additional dimension (Q13A: How much did the pain medication help) if Q13: did you take any medicine for pain is answered yes. Each item is scored on a 1 to 4 Likert scale (1 = Not at all, 4 = Very much) and then linearly transformed to a 0-100 scale. Improvements in QoL are indicated by decreased scores for the 13 main dimensions and an increased score for question 13A. |
| Percentage of Participants With Adverse Events (AEs) | From baseline until end of study, assessed up to approximately 50 months | An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a participant or clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. Treatment Emergent Adverse Events (TEAEs) in this study are events that started after the first dose of study treatment and until 30 days after last dose. |
| Trough Concentration of Trametinib | Pre-dose sample at visits week 3, 6 and 12 | Plasma concentration of trametinib were calculated by visit/sampling time point and summarized using descriptive statistics. |
Countries
China
Participant flow
Recruitment details
This study was conducted at 7 centers in China.
Participants by arm
| Arm | Count |
|---|---|
| Dabrafenib in Combination With Trametinib Dabrafenib 150 mg twice daily, trametinib 2 mg once daily | 40 |
| Total | 40 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 5 |
| Overall Study | Lost to Follow-up | 1 |
| Overall Study | Physician Decision | 4 |
| Overall Study | Progressive Disease | 18 |
| Overall Study | Withdrawal by Subject | 3 |
Baseline characteristics
| Characteristic | Dabrafenib in Combination With Trametinib |
|---|---|
| Age, Continuous | 62.1 Years STANDARD_DEVIATION 7.31 |
| Race/Ethnicity, Customized Chinese | 40 Participants |
| Sex: Female, Male Female | 21 Participants |
| Sex: Female, Male Male | 19 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 6 / 40 | 12 / 16 |
| other Total, other adverse events | 39 / 40 | 1 / 16 |
| serious Total, serious adverse events | 20 / 40 | 1 / 16 |
Outcome results
Primary
Overall Response Rate (ORR), Central Independent Review Assessed by RECIST v1.1
Overall Response Rate (ORR) was defined as the proportion of participants with best overall response (BOR) of complete response (CR) or partial response (PR), as per central independent review assessment and according to RECIST 1.1.
Time frame: From baseline until disease progression, death, lost to follow-up or withdrawal of consent, whichever occurs first, assessed up to approximately 50 months from treatment initiation
Population: Full Analysis Set (FAS)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dabrafenib in Combination With Trametinib | Overall Response Rate (ORR), Central Independent Review Assessed by RECIST v1.1 | 75 Percentage (%) of responders |
Secondary
Duration of Response (DoR), Investigator Assessed by RECIST v1.1
Duration of Response (DoR) only applies to participants whose Best Overall Response (BOR) was complete response (CR) or partial response (PR) according to RECIST 1.1 based on tumor response data per local review. The start date is the date of first documented response of CR or PR (i.e. the start date of response, not the date when response was confirmed), and the end date is defined as the date of the first documented progression or death due to any cause. Participants continuing without progression or death were censored at the date of their last adequate tumor assessment.
Time frame: From first documented response until first documented progression or death due to any cause, whichever occurs first, assessed up to approximately 50 months from treatment initiation
Population: Full Analysis Set (FAS) - Subset of participants per local review with confirmed Best Overall Response (BOR) of complete response (CR) or partial response (PR)
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Dabrafenib in Combination With Trametinib | Duration of Response (DoR), Investigator Assessed by RECIST v1.1 | 14.9 Months |
Secondary
Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) Scale
The EORTC QLQ-C30 is a 30-item questionnaire that patients complete, consisting of both multi-item scales and single-item measures. It includes five functional scales, three symptom scales, six single items, and a Global Health Status/Quality of Life (GHS/QoL) scale. The GHS/QoL scale has seven possible response scores ranging from 1 (very poor) to 7 (excellent), which are averaged and transformed to a 0-100 scale. A higher score on this scale indicates a better quality of life. The change from baseline in GHS/QoL scores is calculated. A positive change from baseline indicated improvement in the patient's quality of life.
Time frame: Baseline (BL), Week 12, End of Treatment (up to approximately 50 months after treatment initiation)
Population: Full Analysis Set (FAS) - Subset of participants with evaluable data at the pre-specified time points
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) Scale | Global Health Status - Change from BL @ Week 12 | 0.18 Score on a Scale | Standard Deviation 0.882 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) Scale | Global Health Status - Change from BL @ End of Treatment (EOT) Disposition | -0.06 Score on a Scale | Standard Deviation 0.938 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) Scale | Quality of Life - Change from BL @ End of Treatment (EOT) Disposition | -0.28 Score on a Scale | Standard Deviation 0.669 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) Scale | Quality of Life - Change from BL @ Week 12 | 0.06 Score on a Scale | Standard Deviation 0.747 |
Secondary
Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13)
The EORTC QLQ-LC13 is a lung cancer-specific module designed to supplement the EORTC QLQ-C30 core questionnaire. It focuses on symptoms and side effects particularly relevant to lung cancer patients, including: Cough, Dyspnea (Shortness of breath), Hemoptysis (Coughing up blood), Sore Mouth/Tongue, Dysphagia (Trouble swallowing), Peripheral neuropathy (Tingling Hands/Feet), Alopecia (Hair Loss) and Pain in chest, arm, shoulder, or other areas and an additional dimension (Q13A: How much did the pain medication help) if Q13: did you take any medicine for pain is answered yes. Each item is scored on a 1 to 4 Likert scale (1 = Not at all, 4 = Very much) and then linearly transformed to a 0-100 scale. Improvements in QoL are indicated by decreased scores for the 13 main dimensions and an increased score for question 13A.
Time frame: Baseline (BL), Week 12, End of Treatment (up to approximately 50 months after treatment initiation)
Population: Full Analysis Set (FAS) - Subset of participants with evaluable data at the pre-specified time points
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Cough - Change from BL @ Week 12 | -0.52 Score on a Scale | Standard Deviation 0.712 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Cough - Change from BL @ End of Treatment (EOT) Disposition | -0.65 Score on a Scale | Standard Deviation 0.606 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Cough up blood - Change from BL @ Week 12 | -0.12 Score on a Scale | Standard Deviation 0.331 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Cough up blood - Change from BL @ End of Treatment (EOT) Disposition | 0.00 Score on a Scale | Standard Deviation 0 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Shortness of breath when walking - Change from BL @ End of Treatment (EOT) Disposition | 0.00 Score on a Scale | Standard Deviation 0.791 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Shortness of breath when climbing stairs - Change from BL @ Week 12 | -0.09 Score on a Scale | Standard Deviation 0.805 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Shortness of breath when climbing stairs - Change from BL @ End of Treatment (EOT) Disposition | -0.18 Score on a Scale | Standard Deviation 0.809 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Sore Mouth/Tongue - Change from BL @ Week 12 | 0.03 Score on a Scale | Standard Deviation 0.305 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Sore Mouth/Tongue - Change from BL @ End of Treatment (EOT) Disposition | 0.06 Score on a Scale | Standard Deviation 0.243 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Trouble swallowing - Change from BL @ Week 12 | -0.03 Score on a Scale | Standard Deviation 0.305 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Trouble swallowing - Change from BL @ End of Treatment (EOT) Disposition | -0.06 Score on a Scale | Standard Deviation 0.429 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Tingling Hands/Feet - Change from BL @ Week 12 | 0.06 Score on a Scale | Standard Deviation 0.348 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Tingling Hands/Feet - Change from BL @ End of Treatment (EOT) Disposition | 0.29 Score on a Scale | Standard Deviation 0.686 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Hair Loss - Change from BL @ Week 12 | -0.03 Score on a Scale | Standard Deviation 0.394 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Hair Loss - Change from BL @ End of Treatment (EOT) Disposition | -0.06 Score on a Scale | Standard Deviation 0.556 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Pain in Arm/Shoulder - Change from BL @ Week 12 | -0.18 Score on a Scale | Standard Deviation 0.528 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Pain in Arm/Shoulder - Change from BL @ End of Treatment (EOT) Disposition | -0.06 Score on a Scale | Standard Deviation 0.659 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Pain in Other Body Areas - Change from BL @ Week 12 | -0.30 Score on a Scale | Standard Deviation 0.585 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Any medicine for pain? - Change from BL @ Week 12 | -0.21 Score on a Scale | Standard Deviation 0.415 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Any medicine for pain? - Change from BL @ End of Treatment (EOT) Disposition | -0.06 Score on a Scale | Standard Deviation 0.429 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Pain Medication Helpful? - Change from BL @ Week 12 | 0.67 Score on a Scale | Standard Deviation 0.577 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Pain Medication Helpful? - Change from BL @ End of Treatment (EOT) Disposition | 0.50 Score on a Scale | Standard Deviation 0.707 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Shortness of breath when resting - Change from BL @ Week 12 | -0.03 Score on a Scale | Standard Deviation 0.394 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Shortness of breath when resting - Change from BL @ End of Treatment (EOT) Disposition | 0.12 Score on a Scale | Standard Deviation 0.332 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Shortness of breath when walking - Change from BL @ Week 12 | -0.12 Score on a Scale | Standard Deviation 0.65 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Pain in chest - Change from BL @ Week 12 | -0.15 Score on a Scale | Standard Deviation 0.508 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Pain in chest - Change from BL @ End of Treatment (EOT) Disposition | -0.06 Score on a Scale | Standard Deviation 0.429 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Lung Cancer Specific Module (EORTC QLQ-LC13) | Pain in Other Body Areas - Change from BL @ End of Treatment (EOT) Disposition | -0.35 Score on a Scale | Standard Deviation 0.493 |
Secondary
Mean Change From Baseline in the European Quality of Life (EuroQol)- 5 Dimensions, 5 Level Questionnaire (EQ-5D-5L)
The EQ-5D-5L is a standardized tool for measuring health-related quality of life (HRQoL). The instrument includes a descriptive system and a visual analogue scale. The descriptive system covers five dimensions (Mobility, Self-care, Usual activities, Pain/discomfort, Anxiety/depression), each with five severity levels ranging from 0 (no problems) to 5 (extreme problems) resulting in a 5-digit health code. In China, a country-specific value set is used to convert the five-digit health state into a utility score, ranging from \<0 (worse than death) to 1.0 (perfect health). A positive change from baseline indicates improvement; a negative change indicates deterioration. The Visual Analog Scale (VAS) is a 0-100 self-rated health scale, where 0 is the worst and 100 the best imaginable health. A positive change reflects perceived improvement.
Time frame: Baseline (BL), Week 12, End of Treatment (up to approximately 50 months after treatment initiation)
Population: Full Analysis Set (FAS) - Subset of participants with evaluable data at the pre-specified time points
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Quality of Life (EuroQol)- 5 Dimensions, 5 Level Questionnaire (EQ-5D-5L) | Anxiety/Depression - Change from BL @ Week 12 | -0.03 Score on a Scale | Standard Deviation 0.467 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Quality of Life (EuroQol)- 5 Dimensions, 5 Level Questionnaire (EQ-5D-5L) | Pain/Discomfort - Change from BL @ End of Treatment (EOT) Disposition | -0.17 Score on a Scale | Standard Deviation 0.618 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Quality of Life (EuroQol)- 5 Dimensions, 5 Level Questionnaire (EQ-5D-5L) | Anxiety/Depression - Change from BL @ End of Treatment (EOT) Disposition | 0.11 Score on a Scale | Standard Deviation 0.583 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Quality of Life (EuroQol)- 5 Dimensions, 5 Level Questionnaire (EQ-5D-5L) | Visual Analog Scale (VAS) - Change from BL @ Week 12 | 1.09 Score on a Scale | Standard Deviation 8.611 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Quality of Life (EuroQol)- 5 Dimensions, 5 Level Questionnaire (EQ-5D-5L) | Visual Analog Scale (VAS) - Change from BL @ End of Treatment (EOT) Disposition | -1.33 Score on a Scale | Standard Deviation 10 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Quality of Life (EuroQol)- 5 Dimensions, 5 Level Questionnaire (EQ-5D-5L) | Mobility - Change from BL @ Week 12 | -0.09 Score on a Scale | Standard Deviation 0.631 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Quality of Life (EuroQol)- 5 Dimensions, 5 Level Questionnaire (EQ-5D-5L) | Mobility - Change from BL @ End of Treatment (EOT) Disposition | 0.06 Score on a Scale | Standard Deviation 0.725 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Quality of Life (EuroQol)- 5 Dimensions, 5 Level Questionnaire (EQ-5D-5L) | Self-Care - Change from BL @ Week 12 | 0.33 Score on a Scale | Standard Deviation 0.174 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Quality of Life (EuroQol)- 5 Dimensions, 5 Level Questionnaire (EQ-5D-5L) | Self-Care - Change from BL @ End of Treatment (EOT) Disposition | 0.11 Score on a Scale | Standard Deviation 0.323 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Quality of Life (EuroQol)- 5 Dimensions, 5 Level Questionnaire (EQ-5D-5L) | Usual Activities - Change from BL @ Week 12 | 0.00 Score on a Scale | Standard Deviation 0.433 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Quality of Life (EuroQol)- 5 Dimensions, 5 Level Questionnaire (EQ-5D-5L) | Usual Activities - Change from BL @ End of Treatment (EOT) Disposition | 0.17 Score on a Scale | Standard Deviation 0.383 |
| Dabrafenib in Combination With Trametinib | Mean Change From Baseline in the European Quality of Life (EuroQol)- 5 Dimensions, 5 Level Questionnaire (EQ-5D-5L) | Pain/Discomfort - Change from BL @ Week 12 | -0.33 Score on a Scale | Standard Deviation 0.816 |
Secondary
Overall Response Rate (ORR), Investigator Assessed by RECIST v1.1
Overall Response Rate (ORR) was defined as the proportion of participants with best overall response (BOR) of complete response (CR) or partial response (PR) by Investigator assessment as per RECIST 1.1 criteria.
Time frame: From baseline until disease progression, death, lost to follow-up or withdrawal of consent, whichever occurs first, assessed up to approximately 50 months from treatment initiation
Population: Full Analysis Set (FAS)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dabrafenib in Combination With Trametinib | Overall Response Rate (ORR), Investigator Assessed by RECIST v1.1 | 77.5 Percentage (%) of responders |
Secondary
Overall Survival (OS)
Overall Survival (OS) was defined as the time from date of first dose to date of death due to any cause. If a participant was not known to have died, then OS was censored at the latest date the participant was known to be alive (on or before the cut-off date).
Time frame: From baseline until death due to any cause, assessed up to approximately 50 months from treatment initiation
Population: Full Analysis Set (FAS)
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Dabrafenib in Combination With Trametinib | Overall Survival (OS) | 25.3 Months |
Secondary
Percentage of Participants With Adverse Events (AEs)
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a participant or clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. Treatment Emergent Adverse Events (TEAEs) in this study are events that started after the first dose of study treatment and until 30 days after last dose.
Time frame: From baseline until end of study, assessed up to approximately 50 months
Population: Full Analysis Set (FAS)
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Dabrafenib in Combination With Trametinib | Percentage of Participants With Adverse Events (AEs) | Adverse Events (AEs) | 39 Participants |
| Dabrafenib in Combination With Trametinib | Percentage of Participants With Adverse Events (AEs) | Treatment related AEs | 37 Participants |
| Dabrafenib in Combination With Trametinib | Percentage of Participants With Adverse Events (AEs) | AEs with grade >= 3 | 27 Participants |
| Dabrafenib in Combination With Trametinib | Percentage of Participants With Adverse Events (AEs) | Treatment related AEs with grade >= 3 | 18 Participants |
| Dabrafenib in Combination With Trametinib | Percentage of Participants With Adverse Events (AEs) | Serious Adverse Events (SAEs) | 20 Participants |
| Dabrafenib in Combination With Trametinib | Percentage of Participants With Adverse Events (AEs) | Treatment related SAEs | 11 Participants |
| Dabrafenib in Combination With Trametinib | Percentage of Participants With Adverse Events (AEs) | Fatal SAEs | 1 Participants |
| Dabrafenib in Combination With Trametinib | Percentage of Participants With Adverse Events (AEs) | Treatment related Fatal SAEs | 0 Participants |
| Dabrafenib in Combination With Trametinib | Percentage of Participants With Adverse Events (AEs) | Adverse Events (AEs) leading to discontinuation | 7 Participants |
| Dabrafenib in Combination With Trametinib | Percentage of Participants With Adverse Events (AEs) | Treatment related AEs leading to discontinuation | 5 Participants |
| Dabrafenib in Combination With Trametinib | Percentage of Participants With Adverse Events (AEs) | AEs leading to dose adjustment/interruption | 30 Participants |
| Dabrafenib in Combination With Trametinib | Percentage of Participants With Adverse Events (AEs) | AEs requiring additional therapy | 38 Participants |
Secondary
Progression Free Survival (PFS), Investigator Assessed by RECIST v1.1
Progression Free Survival (PFS) was defined as the time from the date of first dose to the date of the first documented progression or death due to any cause. PFS was assessed via local review according to RECIST 1.1. PFS was censored if no PFS event was observed before the first to occur between: (i) the analysis cut-off date, and (ii) the date when a new anti-neoplastic therapy is started. The censoring date was the date of the last adequate tumor assessment prior to cut-off/start of new anti-neoplastic therapy.
Time frame: From baseline until disease progression or death due to any cause, whichever occurs first, assessed up to approximately 50 months from treatment initiation
Population: Full Analysis Set (FAS)
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Dabrafenib in Combination With Trametinib | Progression Free Survival (PFS), Investigator Assessed by RECIST v1.1 | 13.9 Months |
Secondary
Trough Concentration of Dabrafenib
Plasma concentration of dabrafenib were calculated by visit/sampling time point and summarized using descriptive statistics.
Time frame: Pre-dose sample at visits week 3, 6 and 12
Population: Pharmacokinetic Analysis Set (PAS) - Participants with corresponding evaluable PK parameters
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Dabrafenib in Combination With Trametinib | Trough Concentration of Dabrafenib | Week 3 (0 hours pre-dose) | 74.4 ng/mL | Geometric Coefficient of Variation 74.9 |
| Dabrafenib in Combination With Trametinib | Trough Concentration of Dabrafenib | Week 6 (0 hours pre-dose) | 91.5 ng/mL | Geometric Coefficient of Variation 109.7 |
| Dabrafenib in Combination With Trametinib | Trough Concentration of Dabrafenib | Week 12 (0 hours pre-dose) | 93.9 ng/mL | Geometric Coefficient of Variation 212 |
Secondary
Trough Concentration of Dabrafenib Metabolites (Hydroxy-dabrafenib, and Desmethyl-dabrafenib)
Plasma concentration of dabrafenib metabolites (hydroxy-dabrafenib, and desmethyl-dabrafenib) were calculated by visit/sampling time point and summarized using descriptive statistics.
Time frame: Pre-dose sample at visits week 3, 6 and 12
Population: Pharmacokinetic Analysis Set (PAS) - Participants with corresponding evaluable PK parameters
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Dabrafenib in Combination With Trametinib | Trough Concentration of Dabrafenib Metabolites (Hydroxy-dabrafenib, and Desmethyl-dabrafenib) | hydroxy-dabrafenib @ Week 12 (0 hours pre-dose) | 100 ng/mL | Geometric Coefficient of Variation 135.6 |
| Dabrafenib in Combination With Trametinib | Trough Concentration of Dabrafenib Metabolites (Hydroxy-dabrafenib, and Desmethyl-dabrafenib) | desmethyl-dabrafenib @ Week 3 (0 hours pre-dose) | 510 ng/mL | Geometric Coefficient of Variation 81.4 |
| Dabrafenib in Combination With Trametinib | Trough Concentration of Dabrafenib Metabolites (Hydroxy-dabrafenib, and Desmethyl-dabrafenib) | hydroxy-dabrafenib @ Week 3 (0 hours pre-dose) | 81.9 ng/mL | Geometric Coefficient of Variation 64.7 |
| Dabrafenib in Combination With Trametinib | Trough Concentration of Dabrafenib Metabolites (Hydroxy-dabrafenib, and Desmethyl-dabrafenib) | hydroxy-dabrafenib @ Week 6 (0 hours pre-dose) | 93.8 ng/mL | Geometric Coefficient of Variation 83.3 |
| Dabrafenib in Combination With Trametinib | Trough Concentration of Dabrafenib Metabolites (Hydroxy-dabrafenib, and Desmethyl-dabrafenib) | desmethyl-dabrafenib @ Week 6 (0 hours pre-dose) | 468 ng/mL | Geometric Coefficient of Variation 69.2 |
| Dabrafenib in Combination With Trametinib | Trough Concentration of Dabrafenib Metabolites (Hydroxy-dabrafenib, and Desmethyl-dabrafenib) | desmethyl-dabrafenib @ Week 12 (0 hours pre-dose) | 430 ng/mL | Geometric Coefficient of Variation 100.9 |
Secondary
Trough Concentration of Trametinib
Plasma concentration of trametinib were calculated by visit/sampling time point and summarized using descriptive statistics.
Time frame: Pre-dose sample at visits week 3, 6 and 12
Population: Pharmacokinetic Analysis Set (PAS) - Participants with corresponding evaluable PK parameters
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Dabrafenib in Combination With Trametinib | Trough Concentration of Trametinib | Week 6 (0 hours pre-dose) | 13.0 ng/mL | Geometric Coefficient of Variation 29.5 |
| Dabrafenib in Combination With Trametinib | Trough Concentration of Trametinib | Week 12 (0 hours pre-dose) | 11.7 ng/mL | Geometric Coefficient of Variation 37 |
| Dabrafenib in Combination With Trametinib | Trough Concentration of Trametinib | Week 3 (0 hours pre-dose) | 12.7 ng/mL | Geometric Coefficient of Variation 35 |